MedPath

Diphenhydramine

Generic Name
Diphenhydramine
Brand Names
Acetadryl, Advil PM, Aleve PM, Allegra Cooling Relief Anti-itch, Banophen, Benadryl, Benadryl Itch Stopping, Benadryl-D Allergy and Sinus, Calagel, Damylin With Codeine, Dimetapp Nighttime Cold & Congestion, Diphen, Diphenhist, Diphenist, Excedrin PM Triple Action, Goody's PM, Legatrin PM, Motrin PM, Nytol, Nytol Quickgels, Percogesic Reformulated Jan 2011, Siladryl, Simply Sleep, Sleepinal, Sominex, Triaminic Night Time Cold & Cough, Tylenol PM, Unisom, Unisom Sleep, Vanamine, Wal-dryl, Wal-som (doxylamine), Zzzquil
Drug Type
Small Molecule
Chemical Formula
C17H21NO
CAS Number
58-73-1
Unique Ingredient Identifier
8GTS82S83M
Background

Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes . However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties . As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system . While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for "night time" use .

Diphenhydramine is also used in combination with 8-chlorotheophylline as the anti-nausea drug Dimenhydrinate where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system .

Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid . As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties.

Indication

Diphenhydramine is a first-generation histamine H1 receptor antagonist (H1 antihistamine) that is widely available as a non-prescription, over-the-counter (OTC) medication. As an OTC medication, diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing, runny nose, itchy/watery eyes, itching of nose or throat, insomnia, pruritis, urticaria, insect bites/stings, allergic rashes, and nausea .

Additionally, when the use of oral diphenhydramine is impractical, there are also prescription-only formulations such as diphenhydramine injection products that are effective in adults and pediatric patients (other than premature infants and neonates) for:

i) the amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after acute allergic reaction symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated ;

ii) the active treatment of motion sickness ; and

iii) use in parkinsonism when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents .

Associated Conditions
Allergic Reaction, Allergic Rhinitis (AR), Allergic cough, Allergy to Tree Pollen, Anaphylaxis, Angioedema, Common Cold, Conjunctival irritation, Cough, Cough Variant Asthma, Cough caused by Common Cold, Eye allergy, Fever, Insect Bites, Insect Stings, Insomnia, Irritative cough, Itching of the nose, Itching of the throat, Motion Sickness, Nasal Congestion, Oral Mucositis, Pain, Parkinsonian Syndromes, Productive cough, Pruritus, Rash, Rhinorrhoea, Sinus Congestion, Sinus headache, Skin Irritation, Sneezing, Sunburn, Symptoms of Acute Bronchitis Accompanied by Coughing, Upper respiratory tract hypersensitivity reaction, site unspecified, Urticaria, Cold or flu syndrome, Dermatographism, Dry cough, Watery itchy eyes
Associated Therapies
Airway secretion clearance therapy, Expectorant

Efficacy and Safety of the Herbal Medicine Sominex ® (Passiflora Incarnata L., Valeriana Officinalis L. and Crataegus Oxyacantha L.), Manufactured by the Laboratory EMS S / A in Patients With Psychophysiological Insomnia

Phase 3
Conditions
Insomnia
Interventions
Drug: Placebo
First Posted Date
2010-04-09
Last Posted Date
2010-10-28
Lead Sponsor
Azidus Brasil
Target Recruit Count
100
Registration Number
NCT01100645
Locations
🇧🇷

LAL Clinica Pesquisa e Desenvolvimento Ltda, Valinhos, São Paulo, Brazil

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Phase 2
Completed
Conditions
Systemic Sclerosis-Associated PAH
Interventions
Biological: Rituximab
Other: Placebo
Diagnostic Test: CMRI
First Posted Date
2010-03-15
Last Posted Date
2023-02-21
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
57
Registration Number
NCT01086540
Locations
🇺🇸

University of Colorado Health Sciences Center, Aurora, Colorado, United States

🇺🇸

University of Minnesota Health Clinics and Surgery Center, Minneapolis, Minnesota, United States

🇺🇸

Boston University Medical Center, Boston, Massachusetts, United States

and more 14 locations

Rescue Emetic Therapy for Children Having Elective Surgery

Not Applicable
Withdrawn
Conditions
Post Operative Nausea and Vomiting
Rescue Emetic Therapy
Interventions
Drug: Saline
Drug: Metaclopramide
First Posted Date
2010-02-11
Last Posted Date
2017-11-14
Lead Sponsor
Franklyn Cladis
Registration Number
NCT01067677
Locations
🇺🇸

The Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Phase 2
Active, not recruiting
Conditions
Hairy Cell Leukemia
Interventions
Drug: Antihistamines
Drug: Corticosteroids
Drug: Bronchodilators
Other: Intravenous (IV) Saline
First Posted Date
2010-02-01
Last Posted Date
2025-04-08
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
69
Registration Number
NCT01059786
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

Phase 2
Completed
Conditions
Cancer
Solid Tumor
Interventions
First Posted Date
2009-11-23
Last Posted Date
2015-06-10
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
68
Registration Number
NCT01017731
Locations
🇺🇸

ImClone Investigational Site, Seattle, Washington, United States

Study on the Development of Opioid Induced Hyperalgesia (OIH) After Exposure to Alfentanil

Not Applicable
Completed
Conditions
Hyperalgesia
Interventions
First Posted Date
2009-10-08
Last Posted Date
2017-10-06
Lead Sponsor
Johns Hopkins University
Target Recruit Count
22
Registration Number
NCT00991809
Locations
🇺🇸

Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

Chicago Social Drinking Project

Not Applicable
Active, not recruiting
Conditions
Alcoholism
Interventions
First Posted Date
2009-08-19
Last Posted Date
2025-02-07
Lead Sponsor
University of Chicago
Target Recruit Count
800
Registration Number
NCT00961792
Locations
🇺🇸

Clinical Addictions Research Laboratory, Chicago, Illinois, United States

Adjunct Sedatives in Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures

Phase 4
Completed
Conditions
Endoscopic Retrograde Cholangiopancreatography (ERCP)
Endoscopic Ultrasound (EUS)
Interventions
First Posted Date
2009-07-13
Last Posted Date
2024-02-26
Lead Sponsor
University of California, Irvine
Target Recruit Count
304
Registration Number
NCT00937924
Locations
🇺🇸

H.H. Chao Comprehensive Digestive Disease Center, Orange, California, United States

Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood

Phase 1
Completed
Conditions
Leukemia, Acute Myelogenous (AML)
Leukemia, Acute Lymphocytic (ALL)
Myelodysplastic Syndrome (MDS)
Non-Hodgkin's Lymphoma (NHL)
Leukemia, Chronic Myelogenous (CML)
Interventions
Drug: Donor Lymphocytes
Drug: WT1 Peptide-Pulsed Dendritic Cells
Drug: WT1 Peptides
Drug: Endotoxin
First Posted Date
2009-06-18
Last Posted Date
2017-04-12
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
10
Registration Number
NCT00923910
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Phase 2
Completed
Conditions
Transplantation, Autologous
Multiple Myeloma
Blood and Marrow Transplant (BMT)
Transplantation, Homologous
Interventions
Procedure: Autologous peripheral blood stem cells (auto-PBSC) transplantation
Procedure: Allogeneic peripheral blood stem cells (allo-PBSC) transplantation
Radiation: Total lymphoid irradiation
Biological: Rabbit anti-thymocyte globulin
Drug: Solumedrol
First Posted Date
2009-05-12
Last Posted Date
2017-10-20
Lead Sponsor
Stanford University
Target Recruit Count
9
Registration Number
NCT00899847
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

© Copyright 2025. All Rights Reserved by MedPath